DVAX Earnings Prediction
The chart below shows how DVAX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DVAX sees a +2.42% change in stock price 10 days leading up to the earnings, and a +2.72% change 10 days following the report. On the earnings day itself, the stock moves by -0.34%. This data can give you a slight idea of what to expect for the next quarter's release.
DVAX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
72.03M
29.56%
-10.66%
Gross Margin
81.38%
-3.54%
-2.85%
Operating Margin
-2.27%
-81.98%
-118.16%
Net Margin
9.79%
2410.26%
-55.13%
EPS
0.05
--
-54.55%
No Data Available
DVAX Earnings Analysis
Dynavax Technologies Corp Corporation (DVAX.O) Earnings Conference Call
Positive
HEPLISAV-B Revenue Milestone: Dynavax achieved record fourth quarter and annual HEPLISAV-B product revenue, with net revenues of $71 million for Q4 and $268 million for the full year 2024, reflecting significant growth compared to the prior year.
Gross Margin Improvement: The company reported a gross margin of 82% for HEPLISAV-B for the full year 2024, an increase from 76% in 2023, and expects to maintain around 80% gross margin in 2025.
HEPLISAV-B Market Share Growth: Dynavax's HEPLISAV-B market share increased to 44% by the end of 2024, demonstrating effective competition against established products in the hepatitis B vaccine market.
Hepatitis B Vaccine Market Growth: The adult hepatitis B vaccination market is expanding, with a nearly 10% year-over-year growth in 2024, creating a larger addressable patient population for vaccines in the U.S.
HEPLISAV-B Sales Growth: The company expects HEPLISAV-B net product sales to grow between $305 million to $325 million in 2025, representing a 17% year-over-year growth at the midpoint.
Adjusted EBITDA Surge: Dynavax's adjusted EBITDA, excluding stock-based compensation, was $52 million for the full year 2024, up over 300% compared to the prior year, indicating strong financial performance.
Shingles Vaccine Trial Results: The shingles vaccine program, Z-1018, showed promising results in Phase 1 trials, with favorable tolerability compared to Shingrix and comparable immune response rates, setting the stage for future studies.
Strong Financial Position: Dynavax has a strong financial position with cash equivalents and marketable securities of $714 million, allowing for continued investment in growth and shareholder returns through share repurchase programs.
Negative
Market Share Challenges: HEPLISAV-B market share growth was flat year-over-year in key segments despite overall revenue growth, indicating potential challenges in expanding market presence.
R&D Expense Increase: R&D expenses increased significantly by 32% year-over-year in Q4 and are expected to rise further in 2025, which may impact profitability if not managed effectively.
Regulatory Hurdles for HEPLISAV-B: The company faced a complete response letter from the FDA regarding the four-dose HEPLISAV-B regimen for adults on hemodialysis, indicating regulatory hurdles that could delay product development.
Liquidity Reduction Impact: Cash equivalents and marketable securities decreased from $742 million to $714 million, reflecting a reduction in liquidity due to share repurchase activities, which may limit future investment opportunities.
HEPLISAV-B Revenue Risks: The reliance on HEPLISAV-B for revenue growth poses risks, as any setbacks in its market performance or regulatory approvals could significantly impact overall financial health.
DVAX FAQs
How does DVAX typically perform around its earnings report dates?
Is Dynavax Technologies Corp (DVAX) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DVAX Earning Call Sentiment
Dynavax Technologies Corporation (NASDAQ:DVAX) Q4 2024 Earnings Call Transcript
DVAX.O
0%Positive
The earnings call shows strong financial performance with record sales, improved margins, and profitability. The $200 million share repurchase plan and optimistic HEPLISAV-B market opportunity further boost sentiment. The Q&A highlights strategic focus and confidence in market share durability. Despite some management ambiguity, the overall positive financial metrics and shareholder returns suggest a positive stock price movement, especially for a small-cap stock.
